Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma

British Journal of Cancer
Joaquim BellmuntJonathan E Rosenberg

Abstract

Metastatic urothelial carcinoma (mUC) is a genomically diverse disease with known alterations in the mTOR pathway and tyrosine kinases including FGFR. We investigated the efficacy and safety of combination treatment with everolimus and pazopanib (E/P) in genomically profiled patients with mUC. mUC patients enrolled on a Phase I dose escalation study and an expansion cohort treated with E/P were included. The primary end point was objective response rate (ORR); secondary end points were safety, duration of response (DOR), progression-free survival (PFS) and overall survival (OS). Patients were assessed for mutations and copy number alterations in 300 relevant cancer-associated genes using next-generation sequencing and findings were correlated with outcomes. Time-to-event data were estimated with Kaplan-Meier methods. Of the 23 patients enrolled overall, 19 had mUC. ORR was 21% (one complete response (CR), three partial responses (PR), eight with stable disease (SD). DOR, PFS and OS were 6.5, 3.6, and 9.1 months, respectively. Four patients with clinical benefit (one CR, two PR, one SD) had mutations in TSC1/TSC2 or mTOR and a 5th patient with PR had a FGFR3-TACC3 fusion. Combination therapy with E/P is safe in mUC and select pa...Continue Reading

Associated Clinical Trials

References

Sep 1, 2007·International Journal of Urology : Official Journal of the Japanese Urological Association·Norihito SogaYoshiki Sugimura
Jan 2, 2008·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Jaclyn LoPiccoloPhillip A Dennis
Jan 11, 2008·The New England Journal of Medicine·John J BisslerDavid N Franz
May 10, 2008·The Biochemical Journal·Jingxiang Huang, Brendan D Manning
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Feb 13, 2009·Japanese Journal of Clinical Oncology·Takahito SuyamaMasayuki Maruoka
Jan 23, 2010·Nature Reviews. Cancer·Nicholas Turner, Richard Grose
Jul 28, 2010·Laboratory Investigation; a Journal of Technical Methods and Pathology·Christina Barbara Ching, Donna Elizabeth Hansel
Dec 30, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Heinz-Josef KlümpenDirk J Richel
Apr 29, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·D Mark DaviesJulian R Sampson
Aug 28, 2012·Science·Gopa IyerDavid B Solit
Sep 13, 2012·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Vassiliki A PapadimitrakopoulouBruce E Johnson
Oct 9, 2012·Seminars in Oncology·Sarmad Sadeghi, Jorge A Garcia
Nov 24, 2012·Human Molecular Genetics·Sarah V WilliamsMargaret A Knowles
Apr 6, 2013·Cancer Discovery·Yi-Mi WuArul M Chinnaiyan
Apr 17, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Levi A Garraway
Jan 31, 2014·Nature·UNKNOWN Cancer Genome Atlas Research Network
May 3, 2014·Molecular Cancer Research : MCR·Jaime AcquavivaDavid A Proia
Feb 13, 2016·Molecular Cancer Research : MCR·Katelyn N NelsonDaniel J Donoghue
Feb 18, 2017·The New England Journal of Medicine·Joaquim BellmuntUNKNOWN KEYNOTE-045 Investigators
Apr 5, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrea B ApoloJames L Gulley
May 12, 2017·Drugs·Matthew S FarinaJoaquim Bellmunt

❮ Previous
Next ❯

Citations

Nov 10, 2018·Expert Opinion on Pharmacotherapy·Aly-Khan A Lalani, Guru P Sonpavde
May 18, 2019·American Society of Clinical Oncology Educational Book·Petros GrivasGuru Sonpavde
May 4, 2020·World Journal of Urology·Sanaz GhafouriAlexandra Drakaki
Aug 8, 2020·Expert Review of Anticancer Therapy·Veronica MollicaFrancesco Massari
May 23, 2020·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·A González-Del-AlbaC Suárez
Dec 1, 2020·Expert Review of Anticancer Therapy·Kamaneh Montazeri, Guru Sonpavde
Sep 14, 2020·Cancer Treatment and Research Communications·Nikolaos AndreatosPetros Grivas

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01184326
NCT01004224
NCT02160041

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2022 Meta ULC. All rights reserved